Kailera Therapeutics, Inc. Proceeds from Sale and Maturity of Marketable Securities
Kailera Therapeutics, Inc. (KLRA) reported Proceeds from Sale and Maturity of Marketable Securities of $190.08 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2026-08-12
- Kailera Therapeutics, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2026-06-30 was $118.79M, a 1384.84% increase year-over-year.
- Kailera Therapeutics, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2026-03-31 was $71.30M.
- Kailera Therapeutics, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2025-06-30 was $8.00M.
- Kailera Therapeutics, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2025-03-31 was $0.00.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month |
|---|---|---|
| 2026-06-30 | $118.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $190.08M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $71.30M 10-Q · filed 2026-05-26 | |
| 2025-06-30 | $8.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $8.00M 10-Q · filed 2026-08-12 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |